All News
Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights
In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning.
Read Article
Liver Management in Rheumatoid Arthritis - RNL2021 Highlight
While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr.
Read Article
From Dr. Petryna ( @DrPetryna ) on Pneumonia & RA #RNL2021 :
-PNA most common hospital inf in RA and main cause of hosp mortality
-seropositivity assoc w/increase risk of PNA
-COPD+RA bad combo: increase PNA & mortality
#RheumNow https://t.co/IgXfJTMrcn
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 32 studies shows most forms of arthritis assoc w/ incr risk of CVA (ischemic stroke: RR=1.53 or hemorrhagic stroke: RR=1.45), esp for RA (RR=1.38), AS (RR=1.49), PsA (RR=1.33), gout (RR=1.4) --risk higher with age <45 years (RR=1.46) https://t.co/YDiebrqtbi
Links:
Dr. John Cush RheumNow ( View Tweet)
From @KDAO2011 for #RNL2021
Is it better to taper the steroids or leave it?
SEMIRA study. Tapering off low dose steroids cause more flares and more treatment side effects.
Dr. Buttgereit says keep your low dose steroids (prednisone 5 mg/day or less)
https://t.co/FpQnxUKWwF
Links:
Dr. John Cush RheumNow ( View Tweet)
A prevention trial shows atorvastatin failed to prevent RA onset - 62 pts with preclinical RA (arthralgia, +CCP/RF) randomized to PBO or statin. After 14 mos, arthritis developed in 29% with atorvastatin and 19% with placebo. https://t.co/HikuDkwNu7 https://t.co/QyGy81lgcq
Links:
Dr. John Cush RheumNow ( View Tweet)
Liver Management in RA - #RNL2021 Highlight by @DrPetryna
While RA is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the mgmt of many RA patients.
https://t.co/OeuloDIXMF
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 Highlights: Future Therapeutics for Rheumatoid Arthritis and Lessons Learned
https://t.co/NxLyHeI2f4 https://t.co/df7lPEia0D
Links:
Dr. John Cush RheumNow ( View Tweet)
Claims data analysis (MarketScan, Medicare, Optum) of 87,653 RA patients starting either TNF inhibitor or tofacitinib shows venous thromboembolism (VTE) is rare (<1 per 100) RA Rx with either. VTE risk was same for Tofa and TNFi (HR of 1.13 [0.77-1.65]) https://t.co/UoMQRp12vo
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Fleischmann vs. Dr. Matsumoto: get rid of MTX vs. get rid of biologic in RA remission. Both argue on sustained remission, risk for anti-drug antibodies, longterm safety. Dr. Buch’s perfect answer… “it depends on patient’s preference, cost.” #RNL2021 https://t.co/FBf2uoDx0B
k dao KDAO2011 ( View Tweet)
Adding RTX to leflunomide works but may at ACR50 level. 140 RA pts on LEF given RTX or PBO w/ ongoing LEF. Wk 16, RTX+LEF ACR50=32% (vs PBO 15%; P=0.02), but not wk 24 (27 vs 15%), yet ACR20 was signif. RTX had more SAEs (20 vs 2%) https://t.co/t6Z9m7P2Ur
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: Liver Management in Rheumatoid Arthritis - #RNL2021 Highlight by Dr. Olga Petryna ( @DrPetryna )
https://t.co/OeuloE0yEd https://t.co/qYd1K0dADu
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Buch discusses the differences between difficult to treat vs refractory RA in #RNL2021. @RheumNow https://t.co/TqrHcBt0la
Dr. Rachel Tate uptoTate ( View Tweet)
News Feature: Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease
https://t.co/2P0tdxvZD2 https://t.co/7gfE1CPSEx
Links:
Dr. John Cush RheumNow ( View Tweet)
Early RA pts given steroids (GC) do Not have short or long term benefits from GCs. 180 ERA pts given compared to 294 who did not. 5 yr F/U showed no differences in DAS28-CRP, HAQ or pain between groups. Steroids were used more in seronegative RA. https://t.co/CDUKDgsLRa
Links:
Dr. John Cush RheumNow ( View Tweet)
Using both glucocorticoids & PPI leads to additive risk of osteoporotic fractures - UK database studiedd 12351 RA pts - 1411 w/ OP Fx. Concomitant GCs + PPIs assoc w/ 1.6-fold risk of OP Fx (adj HR: 1.60) vs nonuse; more than 1.2-fold risk w/ either alone https://t.co/vvA6P5LEgs
Links:
Dr. John Cush RheumNow ( View Tweet)
Mavrilimumab (anti-GM-CSF) metanalysis shows gret benefit in #RA - 1145 pts, 3 trials shows significant 12 week responses by: 1) DAS28-CRP remission (RR = 3.31); 2) ACR20 (RR = 2.38); 3) ACR50 (RR = 2.93) & 4) ACR70 (RR = 4.9). Where is it? https://t.co/9L5PFEB1DI
Links:
Dr. John Cush RheumNow ( View Tweet)
Leading the Rheumatoid Arthritis pod with discussions on pneumonia and RA and interstitial lung disease in RA. #RNL2021 https://t.co/psxMTHsOva
Dr. John Cush RheumNow ( View Tweet)
@RheumNow #RNL2021 Dr. Buttgereit on steroids in RA:
2.5 mg/d of prednisone increase total steroid amount in the body by 100% - great therapeutic effect but comes w/plethora of side effects.
Q: how do you feel out long term low dose steroids for RA?
Olga Petryna DrPetryna ( View Tweet)
Metanalysis reveals significant heterogeneity in defining Refractory Disease in RA and polyarticular JIA. Should include: 1) Resistance to multiple drugs w/ different MOAs (≥2bDMARDs) and 2) Persistent symptoms and disease activity https://t.co/CL6Mr3cs7J
Links:
Dr. John Cush RheumNow ( View Tweet)
